AstraZeneca plc (LON:AZN) has been assigned a GBX 5,333 ($65.00) target price by equities researchers at Sanford C. Bernstein in a report released on Wednesday. The firm presently has a a “neutral” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price target would indicate a potential upside of 6.62% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Deutsche Bank AG reaffirmed a “buy” rating and set a GBX 5,600 ($68.25) price target on shares of AstraZeneca plc in a report on Thursday, June 30th. Citigroup Inc. reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Thursday, June 23rd. Societe Generale reaffirmed a “buy” rating and set a GBX 6,900 ($84.10) price target on shares of AstraZeneca plc in a report on Friday, June 24th. Berenberg Bank boosted their target price on AstraZeneca plc from GBX 4,950 ($60.33) to GBX 5,400 ($65.81) and gave the stock a “buy” rating in a report on Tuesday, July 12th. Finally, Bryan, Garnier & Co reissued a “buy” rating on shares of AstraZeneca plc in a report on Thursday, July 28th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 4,966.24 ($60.53).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) traded down 1.17% on Wednesday, hitting GBX 4943.50. The company’s stock had a trading volume of 851,901 shares. The company’s market cap is GBX 62.54 billion. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The stock’s 50 day moving average is GBX 4,996.12 and its 200-day moving average is GBX 4,492.93.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.